SARS-CoV-2 infection in patients with primary central nervous system lymphoma

Abstract

Background

Cancer patients may be at higher risk for severe coronavirus infectious disease-19 (COVID-19); however, the outcome of Primary Central Nervous System Lymphoma (PCNSL) patients with SARS-CoV-2 infection has not been described yet.

Methods

We conducted a retrospective study within the Lymphomes Oculo-Cérébraux national network (LOC) to assess the clinical characteristics and outcome of SARS-CoV-2 infection in PCNSL patients (positive real-time polymerase chain reaction of nasopharyngeal swab or evocative lung computed tomography scan). We compared clinical characteristics between patients with severe (death and/or intensive care unit admission) and mild disease.

Results

Between March and May 2020, 13 PCNSL patients were diagnosed with SARS-CoV-2 infection, 11 (85%) of whom were undergoing chemotherapy at the time of infection. The mortality rate was 23% (3/13), and two additional patients (15%) required mechanical ventilation. Two patients (15%) had no COVID-19 symptoms. History of diabetes mellitus was more common in severe patients (3/5 vs 0/8, p = 0.03). Two patients recovered from COVID-19 after mechanical ventilation during more than two weeks and resumed chemotherapy. In all, chemotherapy was resumed after COVID-19 recovery in nine patients (69%) after a median delay of 16 days (range 3–32), none of whom developed unusual chemotherapy complication nor SARS-Cov2 reactivation.

Conclusion

This preliminary analysis suggests that, while being at higher risk be for severe illness, PCNSL patients with COVID-19 might be treated maximally especially if they achieved oncological response at the time of SARS-CoV-2 infection. Chemotherapy might be resumed without prolonged delay in PCNSL patients with COVID-19.

Electronic supplementary material

The online version of this article (10.1007/s00415-020-10311-w) contains supplementary material, which is available to authorized users.

Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a new betacoronavirus responsible for the coronavirus infectious disease-19 (COVID-19) pandemic [1]. Models estimate that approximately 0.1–0.5% of infected patients die from COVID-19 [2, 3]. Risk factors for severe COVID-19 in the general population include older age, male sex, and personal history of hypertension, obesity and diabetes mellitus [4]. In addition, emerging evidence suggest that cancer patients are at higher risk for severe COVID-19 (i.e., death, invasive ventilation, intensive care unit [ICU] admission) [5–8]. While several factors might explain this observation (e.g., comorbidities, poor health status, and systemic immunosuppression related to both the cancer and its treatment), the supporting evidence has been limited to studies pooling several cancer types [5–10]; therefore, limiting healthcare providers’ ability to understand how COVID-19 severity may vary among cancer patients with various diagnosis, disease characteristics and treatment patterns.

Preliminary analyses aiming to analyze the outcome of SARS-CoV-2 infection in cancer patients suggest that patients with hematological malignancies may have a more severe COVID-19 [11–13]. Two recent reports indeed reported a higher case fatality rate for patients with hematologic malignancies when compared to patients with solid malignancies [6, 14]. However, to our knowledge, the outcome of Primary Central Nervous System Lymphoma (PCNSL) patients with SARS-CoV-2 infection has not been described yet. Given their intensive cancer treatment (anti-CD20 therapy, corticosteroids, high-dose methotrexate) and underlying general and neurological condition, PCNSL patients may constitute a high-risk population for severe COVID-19. Although PCNSL are highly chemosensitive and potentially curable tumors, delays in treatment can be detrimental as PCNSL cells grow rapidly in the absence of treatment. Whether chemotherapy in PCNSL patients with SARS-CoV-2 infection can be suspended to mitigate the risks of both severe infection and cancer progression has not been addressed.

Here, we conducted a retrospective study in two expert centers from the Lymphomes Oculo-Cérébraux (LOC, dedicated to PCNSL care) national network in a high COVID-19 epidemic region to assess the clinical features and outcome of SARS-CoV-2 infection in PCNSL patients.

Methods

Study design and participants

We reviewed individual records of patients followed for PCNSL in two Parisian Hospitals from the national LOC network (La Pitié Salpêtrière and Saint Louis) and selected patients who had a SARS-CoV-2 infection between March 2020, and May 2020. Diagnosis of SARS-CoV-2 infection was based either on a positive real-time polymerase chain reaction (RT-PCR) of nasopharyngeal swab or on lung computed tomography (CT) scans (i.e., ground-glass opacities, multilobe or posterior involvement, bilateral pneumonia distribution [15, 16]). In both hospitals, all patients with PCNSL had systematic screening for SARS-CoV-2 infection with either a RT-PCR screening or a lung CT-scan at the time of admission, regardless of whether they had COVID-19 symptoms. The study was conducted in compliance with the Declaration of Helsinki. Approval was obtained from the local ethics committee (IRB approval 2020CER-202028).

Procedures

Epidemiological, clinical and laboratory data, radiology reports, therapy details and outcomes were obtained retrospectively from electronic medical records. Oncological responses were defined by the International PCNSL Collaborative Group (IPCG) criteria [17]. For RT-PCR, ORF and gene E regions were analyzed; the end result was considered positive if one or the other was positive. The presence of anti-SARS-CoV-2 IgG in the serum was assessed using a chemiluminescent microparticle immunoassay (ARCHITECT i System, Abbott).

Statistical analysis

Continuous variables were expressed as median for abnormally distributed data. Categorical variables were expressed as frequency rates and percentages. Mean were compared using independent group Wilcoxon–Mann–Whitney tests. Proportions for categorical variables were compared using Fischer tests. All statistical analyses were performed using the R software, version 3.6.3 (http://www.r-project.org/). All tests were two-sided and P values of less than 0.05 were regarded as statistically significant. Analyses were not adjusted for multiple comparisons. Findings should be interpreted as exploratory and descriptive.

Results

Patient characteristics

We identified 13 PCNSL patients with confirmed SARS-CoV-2 infection between March and May 2020. Patients’ characteristics at baseline are provided in Table 1. Seven patients were admitted for their PCNSL treatment before SARS-CoV-2 infection first symptoms or diagnosis, while six patients were admitted for the management of COVID-19. The median age was 65 years (range 35–83) and 62% were females. The median delay between PCNSL diagnosis and SARS-CoV-2 infection was 3.7 months (range 1–165 months). Three patients were receiving first-line treatment without response evaluation yet available, six patients had a complete response (CR), two had a partial response (PR), and the remaining two patients had a relapsed or refractory disease. At the time of SARS-CoV-2 infection first symptoms or diagnosis, the majority of the patients (11/13) were undergoing chemotherapy, 7/11 of whom were receiving R-MPV (rituximab, high-dose methorexate, procarbazine, vincristine and methylprednisone) poly-chemotherapy (four CR, one PR, and two not yet evaluated). Two additional patients were undergoing anti-CD20 therapy concomitant with high-dose methotrexate (one PR and one not yet evaluated). In total, nine patients were undergoing anti-CD20 therapy. The two remaining patients were undergoing, respectively, high-dose Methotrexate concomitant with Temozolomide (achieved CR) and lenalidomide (for relapse).

Table 1.

Clinical characteristics of patients with PCNSL and COVID-19

Variable	Total n = 13	Mild n = 8 (61.5%)	Severe n = 5 (38.5%)
Male gender—no. (%)	5 (38.5)	2 (25)	3 (60)
Age, years—no. (%)
18–60	4 (30.8)	3 (37.5)	1 (20)
60–80	8 (61.5)	4 (50)	4 (80)
> 80	1 (7.7)	1 (12.5)	0 (0)
Underlying condition—no. (%)
Obesity (BMI ≥ 30 kg/m2)†	4 (30.8)	2 (25)	2 (50)
Overweight or Obesity (BMI ≥ 25 kg/m2)†	9 (69.2)	5 (62.5)	4 (100)
Diabetes	3 (23.1)	0 (0)*	3 (60)*
High blood pressure	7 (53.8)	5 (62.5)	2 (40)
Delay since initial lymphoma diagnosis, months—median (range)	3.7 (1.0–164.9)	4 (1.6–55.6)	3.1 (1.0–164.9)
KPS at baseline—no. (%)
40–50	5 (38.5)	3 (37.5)	2 (40)
60–70	4 (30.8)	3 (37.5)	1 (20)
80–90	4 (30.8)	2 (25)	2 (40)
Steroids intake at baseline—no. (%)††	3 (23.1)	1 (12.5)	2 (40)
Chemotherapy at baseline—no. (%)#	11 (84.6)	7 (87.5)	4 (80)
Anti-CD20 therapy at baseline—no. (%)	9 (69.2)	6 (75)	3 (60)
Chemotherapy line – median (range)	1 (1 – 5)	1 (1–2)	1 (1–5)
Remission without treatment—no. (%)	1 (7.7)	1 (12.5)	0 (0)
First line—no. (%)	10 (76.9)	7 (87.5)	3 (60)
Fifth line—no. (%)	1 (7.7)	0	1 (20)
Chemotherapy to resume (relapse)—no. (%)	1 (7.7)	0	1 (20)
Hematologic malignancy status—no. (%)
Initial diagnosis or first-line treatment without evaluation	3 (23.1)	2 (25)	1 (20)
Relapsed or refractory	2 (15.4)	0 (0)	2 (40)
Partial response	2 (15.4)	1 (12.5)	1 (20)
Complete response	6 (46.2)	5 (62.5)	1 (20)

^†Data missing for one patient

^†† ≥ 10 mg prednisone-equivalent

^#One patient was treated with revlimid

*p < 0.05 for mild vs severe patients (Mann–Whitney or Fisher test)

Symptoms, diagnosis and treatment of COVID-19

Patients’ COVID-19 symptoms at baseline are provided in Supplementary Table 1. The most common symptom was fever (10 patients). In addition, six patients had cough and six had shortness of breath. Three patients presented with confusion or clear increase in pre-existing confusion. No other neurological symptom was reported. Two patients without COVID-19 symptoms were diagnosed following systematic RT-PCR screening for SARS-CoV-2 at the time of their admission for chemotherapy. All but three patients had an initial positive RT-PCR of nasopharyngeal swab. Two of the remaining patients had a positive RT-PCR after a first negative test, and the last patient had acute respiratory failure with a lung CT-scan showing pulmonary abnormalities consistent with COVID-19 (bilateral ground-glass opacities).

As regard COVID-19 treatment, four patients were treated with hydroxychloroquine (chloroquine derivative), one with anakinra (interleukin 1 antagonist) and one with remdesivir (RNA polymerase inhibitor), according to local guidelines. In addition, three patients underwent corticosteroid therapy (prednisone 1 mg/kg for 7–14 days) because of radiological evidence of pulmonary fibrosis on follow-up lung CT-scans. All patients received anti-thrombotic therapy (either prophylaxis dose, intermediate or therapeutic dose) and none was diagnosed with venous thromboembolism during the course of COVID-19. The number of patients was too small to compare outcomes according to pattern of COVID-19 treatment.

Outcome of SARS-CoV-2 infection

At last follow-up (June 2020), 10 patients (77%) were still alive (see Table 2). The median follow-up was 64 days (range 4–94), 71 days for patients who remained alive (range 33–94), and 4–12 days for the three deceased patients. These three patients, considered ineligible for ICU admission (poor health status, n = 2; refractory PCNSL, n = 2), died shortly following their COVID-19 diagnosis. Two patients required ICU admission for the management of respiratory failure (see Table 2). Nine patients (69%) required oxygen for a median time of 12 days (range 1–73 days) (Fig. 1). Patients were symptomatic for a median duration of 13 days (range 4–88). Finally, two patients developed no COVID-19 symptom, despite having prolonged RT-PCR positivity (46 and 47 days vs 22–28 days for the remaining patients).

Table 2.

COVID-19 severity in patients with PCNSL and COVID-19

Severity—no. (%)	n = 13
Asymptomatic	2 (15.4)
Symptomatic, requiring ≤ 3L/min oxygen	4 (30.8)
Symptomatic, requiring > 3L/min oxygen	2 (15.4)
Requiring mechanical ventilation	2 (15.4)
Death	3 (23.1)

Fig. 1.

Timeline of illness onset, SARS-CoV-2 RNA detection, admission, oxygen therapy, symptom resolution and chemotherapy resumption among the cohort

Among the two patients who required ICU admission, both had extended lesions on the initial lung CT-scan and required mechanical ventilation (one non-invasive for 22 days; one invasive for 48 days) (Fig. 2). Interestingly, both patients achieved good respiratory and general COVID-19 outcome and were discharged from the ICU after 23 and 66 days, respectively.

Fig. 2.

Severe COVID-19 Infection in a 65-year-old patient with PCNSL. a Clinical Timeline. Top, timeline; bottom, brain MRI (left, T1-Gad; right, FLAIR) and lung CT-scan images during initial PCNSL diagnosis (left), SARS-Cov2 infection, and the recovery phase. b–e Evolution of gas exchange parameters during SARS-Cov2 infection

Outcome of PCNSL and evolution after chemotherapy resumption

According to local guidelines, chemotherapy was suspended immediately after SARS-CoV-2 infection diagnosis in all patients under treatment (n = 11), for a median delay of 32 days (range 26–122). During the follow-up period, chemotherapy was resumed in nine patients (69%, all alive patients who were under chemotherapy at baseline). It was postponed for 2–4 weeks in five patients and for more than four weeks in four patients. The median time between the last COVID-19 symptom and chemotherapy resumption was 16 days for the seven symptomatic patients (range 3–32 days) (Fig. 1).

Control RT-PCR were performed before chemotherapy resumption in six patients, of whom two patients (33%) remained positive. Both patients nonetheless resumed their chemotherapy without evidence of SARS-Cov2 reactivation or other related complication. A negative control RT-PCR was further obtained for both patients three weeks after chemotherapy was resumed. Blood serology was performed before chemotherapy resumption in six patients, and only two patients (33%) had a significant IgG rate at the time of chemotherapy resumption (median time after SARS-CoV-2 infection: 30 days [range 26–33]). No systematic CT-scan was performed before chemotherapy resumption.

No unexpected clinical nor biological evolution was observed after chemotherapy was resumed (Supplementary Fig. 1). Of note, both patients admitted in the ICU were also able to resume their induction chemotherapy regimen with high-dose methotrexate. Further evaluation confirmed complete oncological response in both patients (Fig. 2).

Final outcome and prognostic factors

At last follow-up 10/13 patients were alive. Three died shortly following COVID-19 diagnosis, without being admitted to ICU due to adverse prognostic factors at the time of COVID-19 (see above); none died directly from PCNSL progression. All ten alive patients recovered good respiratory function (no oxygen required, no shortness of breath). One patient developed PCNSL progression during the follow-up period. This patient was receiving 1^st line chemotherapy, had a progressive deterioration of general health status with a KPS of 50%, and achieved only partial response at the time of SARS-CoV-2 infection. She remained asymptomatic for SARS-CoV-2 infection and was able to resume chemotherapy but worsened progressively due to PCNSL progression.

To better understand prognostic factors of COVID-19 in PCNSL patients, we performed an exploratory analysis comparing clinical characteristics between patients with severe (death and/or ICU transfer, 5 patients, 38%) and mild disease (8 patients, 62%) (Tables 1, 2, and supplementary Table 1). History of diabetes was less common in mild patients as compared to severe patients (0/8 vs. 3/5, p = 0.03, Supplementary Table 1). The other clinical data at baseline did not differ significantly between mild and severe patients. Patients with severe COVID-19 outcome tended to have received more than one line of chemotherapy for PCNSL (severe disease in 3/10 patients who received only one line of chemotherapy vs 2/3 patients who received more than one line). We found no association between the administration of rituximab (anti-CD20) and severity (severe disease in 3/9 patients who received rituximab vs 1/2 patients who underwent chemotherapy without rituximab). Patients with severe COVID-19 had a significantly higher neutrophil count at baseline (median 4460 vs 1695/mm³, p < 0.05). Other biological data at baseline did not significantly differ according to the prognosis (Supplementary Table 2).

Discussion

To our knowledge, this is the first report of PCNSL patients with SARS-CoV-2 infection. We describe the severity of the infection and prognostic factors of COVID-19 in PCNSL.

Understanding the factors associated with severe COVID-19 is an important public health issue. Our analysis suggests that PCNSL patients might be at higher risk be for severe COVID-19, with 38.5% severe forms and 23% fatality rate in our PCNSL series vs. 6.1–21.4% ICU admission and 7.5% fatality rate reported in the general population [18–20]. The prognosis of SARS-CoV-2 infection in PCNSL patients in our series was comparable with the one reported in patients with solid malignancies, with approximately 25% mortality rate [6, 14], and slightly better than patients with other hematological malignancies (37–61.5% mortality rate) [6, 11, 14, 21]. Of note, our high fatality rate could be explained, at least in part, by limitations of care due to poor prognosis or health status leading to less intensive COVID-19 treatment. Our patients also had a higher median age and more history of diabetes mellitus—two known risk factors for severe disease [22, 23]—than the general population of reported COVID-19 patients, which could in part explain their worse prognosis.

While PCNSL patients are at high-risk for severe COVID-19, the asymptomatic rate of SARS-CoV-2 infection (15% in our series) was identical to that of the general population [24–30]. Our patients had more frequent shortness of breath as reported in the general population: 46% in our series vs 18.7% [18], which was in line with our observation of more severe COVID-19 in the PCNSL population. He and al. also reported more frequent dyspnea in hematological patients as compared to the general population (77% vs 27%) [11]. All patients who underwent chemotherapy at baseline were regularly admitted for treatment, which constitutes a risk factor for SARS-CoV-2 infection.

Our study has several limitations related to its retrospective nature, small sample size due to the low prevalence of PCNSL, and confounding co-variates such as chemotherapy and heterogeneous disease stage. Despite these limitations, our study provides preliminary data which will help clinical decisions regarding the management of COVID-19 in this rare patient population. PCNSL patients who do not receive chemotherapy have a rapidly fatal course. Although current guidelines suggest suspending chemotherapy in cancer patients with COVID-19, the modality for treatment resumption and adjustment are poorly defined. In our series, chemotherapy was resumed after a median delay of 16 days in all patients after COVID-19 clinical recovery, regardless of control SARS-CoV-2 RT-PCR or serology results. We observed no unexpected evolution after chemotherapy resumption, with a median follow-up of 1.5 months.

We report two patients with severe COVID-19 (mechanical ventilation more than 2 weeks) who were both able to resume PCNSL chemotherapy without experiencing disease progression. According to current consensus guidelines [31], decision of ICU transfer and intensity of treatment in cancer patients with COVID-19 should be adjusted depending on the status of the viral outbreak (e.g., current R0 index, basic reproduction number), availability of hospital technical and human resources (e.g., ICU ventilation capacities), as well as risk factors for adverse outcomes. Our data suggests that PCNSL patients might be treated intensively especially if they have reasonable life expectancy (e.g., patients with good performance status, who are in first-line chemotherapy and patients who already achieved a complete or partial response).

In conclusion, our preliminary data suggest that, while being at higher risk for severe illness, PCNSL patients with COVID-19 might be treated intensively especially if they have reasonable life expectancy. No evidence of SARS-Cov2 reactivation was found in PCNSL patients who resumed chemotherapy after COVID-19 clinical recovery. This preliminary data will inform guidelines for the management of PCNSL and cancer patients in the context of COVID-19 and future outbreaks [32–36]. Future studies should address which PCNSL patients have the highest risk for severe COVID-19, the long-term outcomes of COVID-19 in PCNSL patients, and how chemotherapy should be optimized in this population to mitigate the risks of both severe infection and cancer progression.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Author contributions

AL, KHX and MT designed the study. AL, RU, CQ, SC, and MT collected the data. AL and MT reviewed and analyzed the clinical data. AL and MT wrote the initial draft, with input from all authors. All authors participated in data analysis, reviewed and approved the final manuscript.

Funding

This work was in part supported by a grant INCa-DGOS-Inserm_12560 of the SiRIC CURAMUS, Institut National du Cancer (INCa). The Cohort COVID-19 Neurosciences (CoCo Neurosciences) study was sponsored by APHP and funded by the generous support of the FIA (Fédération Internationale pour l’Automobile) Foundation and donors of the Paris Brain Institute – ICM. The research leading to these results has received funding from the program “Investissements d’avenir” ANR-10- IAIHU-06.

Compliance with ethical standards

Conflicts of interest

MT reports consulting or advisory role from Agios Pharmaceutical, Integragen, and Taiho Oncology, outside the submitted work; travel, accommodations, expenses from Merck Sharp & Dome, outside the submitted work. All authors report no disclosures relevant to the manuscript.

Ethical approval

The study was conducted in compliance with the Declaration of Helsinki. Approval was obtained from the local ethics committee (IRB approval 2020CER-202028).

Consent to participate

All patients gave their informed consent prior to their inclusion in the study.

Consent for publication

All authors agreed with the content of the manuscript and all gave explicit consent to submit.